ArticleJournal of inflammation research2026
Transcriptomic and Proteomic Analyses Identify THBS2, VWF, NFASC, and AKR1B10 as Diagnostic Biomarkers for Advanced Fibrosis in NAFLD.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) has paralleled changes in lifestyle and dietary habits. However, the gold standard for the staging of NAFLD relies on liver biopsy, which is highly damaging and poorly accepted. This study aims to identify convenient biomarkers for staging advanced fibrosis (stage F3-F4) in NAFLD patients, thereby improving disease management. Patients and Methods: This study integrated liver transcriptomic sequencing data and peripheral blood proteomic data from NAFLD patients. Candidate diagnostic biomarkers for advanced fibrosis were screened using three machine learning algorithms. The dynamic expression patterns of these biomarkers were further validated by time series analysis from NAFLD mouse model. Additionally, a retrospective validation cohort comprising 119 biopsy-confirmed NAFLD patients was established at Shandong Provincial Hospital. Blood samples and clinical characteristics were collected before liver biopsy. These samples were used to validate the diagnostic performance of the candidate biomarkers via ELISA, which was further compared with established non‑invasive indicators (FIB‑4, APRI, and NFS). Finally, single-nucleus sequencing was employed to elucidate the underlying pathogenic mechanisms and their cellular location in NAFLD, while Mendelian randomization (MR) analyses based on whole proteome and whole genome data were conducted to explore causal relationship for NAFLD. Results: This study identified THBS2, AKR1B10, NFASC, and VWF as diagnostic biomarkers for advanced fibrosis in NAFLD. Transcriptomic and proteomic analyses demonstrated that the combination of these four biomarkers exhibited robust diagnostic performance (AUC = 0.860-0.880). In our NAFLD clinical cohort, each biomarker individually showed promising diagnostic performance (THBS2 AUC = 0.867; NFASC AUC = 0.834; VWF AUC = 0.777; AKR1B10 AUC = 0.733), which was comparable to established non-invasive indicators. Furthermore, the expression levels of THBS2, AKR1B10, and VWF increased progressively with the duration of high-fat diet feeding in NAFLD mouse model. NFASC and THBS2 were specifically enriched in activated hepatic stellate cells and showed significant upregulation in advanced fibrosis and cirrhosis. Conclusion: THBS2, AKR1B10, NFASC, and VWF serve as diagnostic biomarkers for advanced fibrosis in NAFLD, providing novel insights for the development of non-invasive clinical diagnostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.